Early signs from the launch of Novo Nordisk’s Wegovy pill and Eli Lilly & Co.’s Foundayo are making investors rethink the opportunity for GLP-1 pills.
Early signs from the launch of Novo Nordisk’s Wegovy pill and Eli Lilly & Co.’s Foundayo are making investors rethink the opportunity for GLP-1 pills.
